Ocular Therapeutix (OCUL): Chief Development Officer sold ~$21K
Peter Kaiser, Chief Development Officer at Ocular Therapeutix, sold ~$21K of Ocular Therapeutix shares.
- ~$21K
- Approx. value · 3,009 sh @ $6.87
- 210K
- Holds after · shares reported
- Traded
- Feb 24, 2025
- Filed
- Feb 26, 2025
What stands out in this filing
- The sale was 1.4% of the shares this insider held before it; the filing reports 210,078 shares afterwards.
- 3,009 shares at an average of $6.87 each, as reported on the form.
- Footnote references tax withholding.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 31, 2025InsiderOfficer sold ~$49K of OCUL shares in the open market
- Feb 4, 2025InsiderOfficer sold ~$87K of OCUL shares in the open market
- Feb 24, 2025 · this disclosureInsiderOfficer sold ~$21K of OCUL shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Ocular Therapeutix
For Ocular Therapeutix, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OCUL page.
Other recent filings by Peter Kaiser, Chief Development Officer
- SEC Form 4 at Ocular Therapeutix (OCUL)Oct 7, 2026
- SEC Form 4 at Ocular Therapeutix (OCUL)Aug 27, 2025
- SEC Form 4 at Ocular Therapeutix (OCUL)May 27, 2025
- SEC Form 4 at Ocular Therapeutix (OCUL)Nov 27, 2024
The full history of Peter Kaiser, Chief Development Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Ocular Therapeutix (OCUL) insider traded, and how much?
Peter Kaiser, Chief Development Officer at Ocular Therapeutix, sold ~$21K of Ocular Therapeutix shares. 3,009 shares at $6.87.
When did it happen, and when was it made public?
Traded: Feb 24, 2025. Filed: Feb 26, 2025. That is 2 days between the two dates.
What stands out in this filing?
The sale was 1.4% of the shares this insider held before it; the filing reports 210,078 shares afterwards. 3,009 shares at an average of $6.87 each, as reported on the form. Footnote references tax withholding.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Ocular Therapeutix recently?
For Ocular Therapeutix, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the OCUL page.
Does this mean OCUL stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Ocular Therapeutix
- SEC Form 4Nov 9, 2026
- SEC Form 144Nov 5, 2026
- SEC Form 4Oct 13, 2026
- SEC Form 144Oct 8, 2026
- SEC Form 4Oct 7, 2026
- SEC Form 4Oct 7, 2026
Everything OQRO holds on this company is on its OCUL page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data